Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti^® in Knee Cartilage Defects

NCT ID: NCT06249828

Last Updated: 2025-09-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-22

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Subjects aged 50 to 65 years with knee cartilage defects will undergo microfracture treatment for cartilage regeneration and MegaCarti\^® will be applied.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The MegaCarti\^® is the decellularized allogeneic cartilage and acts as a cover after bone marrow stimulation to prevent the loss of blood clots and induces cartilage regeneration by assisting in the location of stem cells derived from bone marrow.

To evaluate cartilage regeneration, the study group is compared with the microfracture group alone through MOCART evaluation at 48 weeks after treatment for cartilage regeneration. In addition, a biopsy is performed to evaluate the formation of hyaline cartilage and the area ratio of regenerated cartilage is measured.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis, Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MegaCarti^® application after Microfracture Surgery

The study group is applied with MegaCarti\^® after microfracture. Afterwards, they visit at 12 weeks, 24 weeks, and 48 weeks to conduct examinations and assess Questionnaires.

Group Type EXPERIMENTAL

MegaCarti^®

Intervention Type DEVICE

MegaCarti® application after microfracture through athroscopic or incision surgery

Microfracture

Intervention Type PROCEDURE

Microfracture through athroscopic or incision surgery

Microfracture Surgery without Medical Devices

The control group undergoes microfracture and they visit at 12 weeks, 24 weeks, and 48 weeks after surgery to conduct examinations and assess Questionnaires.

Group Type ACTIVE_COMPARATOR

Microfracture

Intervention Type PROCEDURE

Microfracture through athroscopic or incision surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MegaCarti^®

MegaCarti® application after microfracture through athroscopic or incision surgery

Intervention Type DEVICE

Microfracture

Microfracture through athroscopic or incision surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 50 years to 65 yaers
2. After receiving a detailed explanation of this clinical trial and fully understanding it, the subject or legal representative voluntarily decides to participate in the clinical trial and sign the consent form
3. Subjects with localized full-thickness cartilage defects in the knee joint, International Cartilage Repair Society(ICRS) Grade III or IV
4. Subjects whose primary lesion site can be designated as one section of the knee joint, and the area can be determined as the main cause of clinical symptoms
5. knee cartilage defect size :1.5cm\^2 to 10cm\^2

Exclusion Criteria

1. Patients who have autoimmune diseases (Ex. Rheumatoid arthritis)
2. When screening, Patients who underwent surgery related to cartilage defect treatment, such as microfracture, autologous chondrocyte therapy within the past 1 year (However, arthroscopy for diagnostic purposes is possible. Additionally, it is possible if hightibial osteotomy (HTO) has been performed in advance or is scheduled)
3. When screening, Patients who received intra-articular hyaluronic acid or steroid injections in the knee within 1 month
4. When screening, Patients who took oral steroid within 2 weeks
5. Patients who can't take MRI scan
6. BMI index : 30kg/m\^2 or over
7. Patients who have gout or gout history in the knee
8. Women who are pregnant or breast-feeding, or women who have a possibility of pregnancy but do not use medically accepted methods of contraception.
9. Patients with risk factor for bleeding
10. Other than above, patients who are judged by medical investigator to be considered unsuitable for this clinical trial
Minimum Eligible Age

50 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

L&C Bio

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sunghwan kim

Role: STUDY_DIRECTOR

Yonsei University College of Medicine Gangnam severance Hospital

Junyoung Chung

Role: STUDY_DIRECTOR

Ajou University Medical Center

Junkyu Lee

Role: STUDY_DIRECTOR

Konkuk University Medical Center

Yongbum Park

Role: STUDY_DIRECTOR

Chung-Ang University Gwangmyeong Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chung-Ang University Gwangmyeong Hospital

Gyeonggi-do, , South Korea

Site Status RECRUITING

Ajou University Medical Center

Gyeonggi-do, , South Korea

Site Status RECRUITING

Catholic Kwandong University International St.Mary's Hospital

Incheon, , South Korea

Site Status RECRUITING

Konkuk University Medical Center

Seoul, , South Korea

Site Status RECRUITING

Yonsei University Health System, Gangnam Severance Hospital

Seoul, , South Korea

Site Status RECRUITING

Yonsei Sarang Hospital

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

JY Ahn

Role: CONTACT

822- 070-7791-2290

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yongbum Park

Role: primary

1811-7800

Junyoung Chung

Role: primary

1688-6114

Chae DongSik

Role: primary

1600-8291

Junkyu Lee

Role: primary

1588-1533

Sunghwan Kim

Role: primary

1599-6114

Jeong JaeHyeon

Role: primary

1577-0050

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LNC-MECA-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NeoCart Phase 2 Clinical Trial
NCT00548119 COMPLETED PHASE2